Global Diabetic Retinopathy Market By Type (Nonproliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy (PDR), By Symptoms (Spots or dark strings floaters, Blurred vision, Fluctuating vision, Dark or empty areas in the vision, Vision loss, Others) By Diagnosis (Fluorescein angiography, Optical coherence tomography (OCT), By Treatment, Anti VEGF Drug, Steroid Implants, Laser Surgeries, Vitrectomy, By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Globally, diabetes retinopathy is a serious health issue. The World Health Organization (WHO) anticipates that there will be up to 285 million cases of diabetes worldwide in the year 2025, according to recent research that have shown a clear rise in the incidence and prevalence of the disease worldwide. If a person has type 1 or type 2 diabetes and a protracted history of uncontrolled high blood sugar levels, they are at a higher risk of diabetic retinopathy. Diabetic patients may experience issues that impair their eyesight. In addition to other ocular conditions, diabetes increases the chance of developing diabetic retinopathy. The most common cause of blindness in young and middle-aged individuals nowadays is diabetic retinopathy. The likelihood of developing diabetic retinopathy increases with the duration of diabetes and blood sugar management. In the last few years, there has been a tremendous rise in the cases of diabetics amongst the huge population. Due to the rising awareness about diabetic retinopathy as well as its early diagnosis has led to the rise of demand in various treatments. Younger generation' diabetic retinopathy (DR) diagnosis and care have greatly advanced in recent years by incorporating spectral optical tomography of the eye along with research methodologies that have greatly expanded. The use of optical coherence tomography and other technologically advanced diagnostic tools produces improved cross-sectional pictures that help doctors make wiser choices. The accuracy of surgical tools has also been improved, which raises the success rates of operations. Therefore, the availability of such advanced ophthalmic gadgets and tools has made diagnostic and surgical operations easier, which has a beneficial effect on the diabetic retinopathy market growth. The industry's expansion may be somewhat constrained by difficulties and unfavourable effects related to the drugs administered to lessen the effects of diabetic retinopathy.
In terms of revenue, global diabetic retinopathy market was valued at US$ 6.6 Bn in 2021 growing at a CAGR of 6.8% over the forecast period (2022 – 2030).
Global Diabetic Retinopathy Market Revenue & Forecast, (US$ Million), 2015 – 2030
Type Outlook
Based on the type, the global diabetic retinopathy market is segmented into nonproliferative diabetic retinopathy and proliferative diabetic retinopathy (PDR). During the forecast period, the proliferative diabetic retinopathy (PDR) segment is anticipated to grow at a faster CAGR. It is regarded as retinopathy's advanced stage. In this instance, the vulnerable blood vessels develop inside the vitreous cavity and retina, leading to hazy vision and blindness. Initially having no symptoms, it may cause macular edoema. Comprehensive eye exams, including tonometry, visual acuity tests, and many more, are used to diagnose it. Laser surgery is used to treat it, allowing the blood vessels to constrict. On the other hand in diabetic patients, non-proliferative is the most frequent cause of blindness. Along with being less chronic than proliferative diabetic retinopathy, non-proliferative diabetic retinopathy affects more people in the 40–60 age range. Since the problem may be managed at an early stage, people with non-proliferative diabetic retinopathy prefer a variety of drugs and therapies.
Treatment Outlook
Based on the treatment, the diabetic retinopathy market is segmented into Anti VEGF Drug, Steroid Implants, Laser Surgeries, Vitrectomy. There are a variety of diabetic retinopathy therapies, depending on the severity of the problem. People with diabetic retinopathy may need laser surgery to stop blood vessels from leaking or to stop other blood vessels from leaking. It may be necessary for an optometrist to inject drugs into the eye to reduce inflammation or inhibit the growth of new blood vessels. A surgical treatment to remove and replace the vitreous, or gel-like fluid in the back of the eye, may be necessary for those with severe diabetic retinopathy. A retinal detachment may potentially require surgery to be repaired. The lining in the rear of the eye that receives light has separated in this way. Laser surgeries are gaining huge popularity amongst the population as usually works very well to prevent vision loss if it's done before the retina has been severely damaged. The severity of diabetic retinopathy could not be restored with laser treatments, which were once the mainstay of therapy; instead, clinicians could only address the underlying reasons of visual loss. With laser therapy, doctors may now correct the severity of visual loss in addition to treating the underlying reasons, which reduces the likelihood that patients will require additional treatment. Thus with the advancements in the treatments for diabetic retinopathy the market globally is expected to flourish in the upcoming years.
Region Outlook
Based on the regions, North America had the highest share in the diabetic retinopathy market in the year 2021. Over 29 million individuals in the United States alone have diabetes, a lifelong chronic condition. Damaged blood vessels in the retina are the major symptoms of the prevalent diabetic eye condition known as diabetic retinopathy (DR). The main causes of the growth in DR in the United States include an ageing population, a high prevalence of obesity, and a rise in sedentary lifestyle. Many initiatives are being taken to fight this illness, beginning with raising awareness of the symptoms, early detection, and treatments. Due to the difficulty in identifying early symptoms, people with DR frequently lack them. Furthermore leading players in the market are focused on introducing advanced treatments and early diagnosis instruments and techniques which has resulted for the highest share in the market.
Competitive Landscape
The report provides both, qualitative and quantitative research of global diabetic retinopathy market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global diabetic retinopathy market are
- Abbott
- AbbVie Inc.
- ALLERGAN
- Ampio Pharmaceuticals, Inc.
- Bayer AG
- BCN Peptides S.A.
- Genentech, Inc,
- Novartis AG,
- Pfizer Inc,
- Regeneron Pharmaceuticals Inc.
- Sirnaomics Ltd
- Other Industry Participants
Global Diabetic Retinopathy Market:
By Type
- Nonproliferative Diabetic Retinopathy
- Proliferative Diabetic Retinopathy (PDR)
By Symptoms
- Spots or dark strings floaters
- Blurred vision
- Fluctuating vision
- Dark or empty areas in the vision
- Vision loss
- Others
By Diagnosis
- Fluorescein angiography
- Optical coherence tomography (OCT)
By Treatment
- Anti VEGF Drug
- Steroid Implants
- Laser Surgeries
- Vitrectomy
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2021
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 – 2030
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Diabetic Retinopathy Market
6.
Market
Synopsis: Diabetic Retinopathy Market
7.
Diabetic
Retinopathy Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Diabetic Retinopathy Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Diabetic Retinopathy Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Diabetic Retinopathy
Market
8.
Global Diabetic
Retinopathy Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global Diabetic Retinopathy Market Revenue
(US$ Mn)
8.2. Global Diabetic Retinopathy Market Revenue
(US$ Mn) and Forecasts, By Type
8.2.1. Nonproliferative Diabetic Retinopathy
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.1.3.
Market
Forecast, 2022 – 2030
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2021
8.2.1.5.1.2. Market Forecast, 2022 – 2030
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2021
8.2.1.5.2.2. Market Forecast, 2022 – 2030
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2021
8.2.1.5.3.2. Market Forecast, 2022 – 2030
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2021
8.2.1.5.4.2. Market Forecast, 2022 – 2030
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2021
8.2.1.5.5.2. Market Forecast, 2022 – 2030
8.2.2. Proliferative Diabetic Retinopathy
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.2.3.
Market
Forecast, 2022 – 2030
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2021
8.2.2.5.1.2. Market Forecast, 2022 – 2030
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2021
8.2.2.5.2.2. Market Forecast, 2022 – 2030
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2021
8.2.2.5.3.2. Market Forecast, 2022 – 2030
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2021
8.2.2.5.4.2. Market Forecast, 2022 – 2030
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2021
8.2.2.5.5.2. Market Forecast, 2022 – 2030
8.3. Key Segment for Channeling Investments
8.3.1. By
Type
9.
Global Diabetic
Retinopathy Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global Diabetic Retinopathy Market Revenue
(US$ Mn) and Forecasts, By Symptoms
9.2.1. Spots or dark strings floaters
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.1.3.
Market
Forecast, 2022 – 2030
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2021
9.2.1.5.1.2. Market Forecast, 2022 – 2030
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2021
9.2.1.5.2.2. Market Forecast, 2022 – 2030
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2021
9.2.1.5.3.2. Market Forecast, 2022 – 2030
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2021
9.2.1.5.4.2. Market Forecast, 2022 – 2030
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2021
9.2.1.5.5.2. Market Forecast, 2022 – 2030
9.2.2. Blurred vision
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.2.3.
Market
Forecast, 2022 – 2030
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2021
9.2.2.5.1.2. Market Forecast, 2022 – 2030
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2021
9.2.2.5.2.2. Market Forecast, 2022 – 2030
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2021
9.2.2.5.3.2. Market Forecast, 2022 – 2030
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2021
9.2.2.5.4.2. Market Forecast, 2022 – 2030
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2021
9.2.2.5.5.2. Market Forecast, 2022 – 2030
9.2.3. Fluctuating vision
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.3.3.
Market
Forecast, 2022 – 2030
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1. Market Estimation, 2015 - 2021
9.2.3.5.1.2. Market Forecast, 2022 – 2030
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2021
9.2.3.5.2.2. Market Forecast, 2022 – 2030
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2021
9.2.3.5.3.2. Market Forecast, 2022 – 2030
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2021
9.2.3.5.4.2. Market Forecast, 2022 – 2030
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2021
9.2.3.5.5.2. Market Forecast, 2022 – 2030
9.2.4. Dark or empty areas in your vision
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.4.3.
Market
Forecast, 2022 – 2030
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1.
North
America
9.2.4.5.1.1. Market Estimation, 2015 - 2021
9.2.4.5.1.2. Market Forecast, 2022 – 2030
9.2.4.5.2.
Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2021
9.2.4.5.2.2. Market Forecast, 2022 – 2030
9.2.4.5.3.
Asia
Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2021
9.2.4.5.3.2. Market Forecast, 2022 – 2030
9.2.4.5.4.
Middle
East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2021
9.2.4.5.4.2. Market Forecast, 2022 – 2030
9.2.4.5.5.
Latin
America
9.2.4.5.5.1. Market Estimation, 2015 - 2021
9.2.4.5.5.2. Market Forecast, 2022 – 2030
9.2.5. Vision loss
9.2.5.1.
Definition
9.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.5.3.
Market
Forecast, 2022 – 2030
9.2.5.4.
Compound
Annual Growth Rate (CAGR)
9.2.5.5.
Regional
Bifurcation
9.2.5.5.1.
North
America
9.2.5.5.1.1. Market Estimation, 2015 - 2021
9.2.5.5.1.2. Market Forecast, 2022 – 2030
9.2.5.5.2.
Europe
9.2.5.5.2.1. Market Estimation, 2015 - 2021
9.2.5.5.2.2. Market Forecast, 2022 – 2030
9.2.5.5.3.
Asia
Pacific
9.2.5.5.3.1. Market Estimation, 2015 - 2021
9.2.5.5.3.2. Market Forecast, 2022 – 2030
9.2.5.5.4.
Middle
East and Africa
9.2.5.5.4.1. Market Estimation, 2015 - 2021
9.2.5.5.4.2. Market Forecast, 2022 – 2030
9.2.5.5.5.
Latin
America
9.2.5.5.5.1. Market Estimation, 2015 - 2021
9.2.5.5.5.2. Market Forecast, 2022 – 2030
9.2.6. Others
9.2.6.1.
Definition
9.2.6.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.6.3.
Market
Forecast, 2022 – 2030
9.2.6.4.
Compound
Annual Growth Rate (CAGR)
9.2.6.5.
Regional
Bifurcation
9.2.6.5.1.
North
America
9.2.6.5.1.1. Market Estimation, 2015 - 2021
9.2.6.5.1.2. Market Forecast, 2022 – 2030
9.2.6.5.2.
Europe
9.2.6.5.2.1. Market Estimation, 2015 - 2021
9.2.6.5.2.2. Market Forecast, 2022 – 2030
9.2.6.5.3.
Asia
Pacific
9.2.6.5.3.1. Market Estimation, 2015 - 2021
9.2.6.5.3.2. Market Forecast, 2022 – 2030
9.2.6.5.4.
Middle
East and Africa
9.2.6.5.4.1. Market Estimation, 2015 - 2021
9.2.6.5.4.2. Market Forecast, 2022 – 2030
9.2.6.5.5.
Latin
America
9.2.6.5.5.1. Market Estimation, 2015 - 2021
9.2.6.5.5.2. Market Forecast, 2022 – 2030
9.3. Key Segment for Channeling Investments
9.3.1. By
Symptoms
10. Global Diabetic Retinopathy Market Analysis
and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global Diabetic Retinopathy Market Revenue
(US$ Mn) and Forecasts, By Diagnosis
10.2.1. Fluorescein angiography
10.2.1.1.
Definition
10.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.1.3.
Market
Forecast, 2022 – 2030
10.2.1.4.
Compound
Annual Growth Rate (CAGR)
10.2.1.5.
Regional
Bifurcation
10.2.1.5.1.
North
America
10.2.1.5.1.1. Market Estimation, 2015 - 2021
10.2.1.5.1.2. Market Forecast, 2022 – 2030
10.2.1.5.2.
Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2021
10.2.1.5.2.2. Market Forecast, 2022 – 2030
10.2.1.5.3.
Asia
Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2021
10.2.1.5.3.2. Market Forecast, 2022 – 2030
10.2.1.5.4.
Middle
East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2021
10.2.1.5.4.2. Market Forecast, 2022 – 2030
10.2.1.5.5.
Latin
America
10.2.1.5.5.1. Market Estimation, 2015 - 2021
10.2.1.5.5.2. Market Forecast, 2022 – 2030
10.2.2. Optical coherence tomography (OCT)
10.2.2.1.
Definition
10.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.2.3.
Market
Forecast, 2022 – 2030
10.2.2.4.
Compound
Annual Growth Rate (CAGR)
10.2.2.5.
Regional
Bifurcation
10.2.2.5.1.
North
America
10.2.2.5.1.1. Market Estimation, 2015 - 2021
10.2.2.5.1.2. Market Forecast, 2022 – 2030
10.2.2.5.2.
Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2021
10.2.2.5.2.2. Market Forecast, 2022 – 2030
10.2.2.5.3.
Asia
Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2021
10.2.2.5.3.2. Market Forecast, 2022 – 2030
10.2.2.5.4.
Middle
East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2021
10.2.2.5.4.2. Market Forecast, 2022 – 2030
10.2.2.5.5.
Latin
America
10.2.2.5.5.1. Market Estimation, 2015 - 2021
10.2.2.5.5.2. Market Forecast, 2022 – 2030
10.3. Key Segment for Channeling Investments
10.3.1. By Diagnosis
11. Global Diabetic Retinopathy Market Analysis
and Forecasts, 2022 – 2030
11.1. Overview
11.2. Global Diabetic Retinopathy Market Revenue
(US$ Mn) and Forecasts, By Treatment
11.2.1. Anti VEGF Drug
11.2.1.1.
Definition
11.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.1.3.
Market
Forecast, 2022 – 2030
11.2.1.4.
Compound
Annual Growth Rate (CAGR)
11.2.1.5.
Regional
Bifurcation
11.2.1.5.1.
North
America
11.2.1.5.1.1. Market Estimation, 2015 - 2021
11.2.1.5.1.2. Market Forecast, 2022 – 2030
11.2.1.5.2.
Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2021
11.2.1.5.2.2. Market Forecast, 2022 – 2030
11.2.1.5.3.
Asia
Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2021
11.2.1.5.3.2. Market Forecast, 2022 – 2030
11.2.1.5.4.
Middle
East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2021
11.2.1.5.4.2. Market Forecast, 2022 – 2030
11.2.1.5.5.
Latin
America
11.2.1.5.5.1. Market Estimation, 2015 - 2021
11.2.1.5.5.2. Market Forecast, 2022 – 2030
11.2.2. Steroid Implants
11.2.2.1.
Definition
11.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.2.3.
Market
Forecast, 2022 – 2030
11.2.2.4.
Compound
Annual Growth Rate (CAGR)
11.2.2.5.
Regional
Bifurcation
11.2.2.5.1.
North
America
11.2.2.5.1.1. Market Estimation, 2015 - 2021
11.2.2.5.1.2. Market Forecast, 2022 – 2030
11.2.2.5.2.
Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2021
11.2.2.5.2.2. Market Forecast, 2022 – 2030
11.2.2.5.3.
Asia
Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2021
11.2.2.5.3.2. Market Forecast, 2022 – 2030
11.2.2.5.4.
Middle
East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2021
11.2.2.5.4.2. Market Forecast, 2022 – 2030
11.2.2.5.5.
Latin
America
11.2.2.5.5.1. Market Estimation, 2015 - 2021
11.2.2.5.5.2. Market Forecast, 2022 – 2030
11.2.3. Laser Surgeries
11.2.3.1.
Definition
11.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.3.3.
Market
Forecast, 2022 – 2030
11.2.3.4.
Compound
Annual Growth Rate (CAGR)
11.2.3.5.
Regional
Bifurcation
11.2.3.5.1.
North
America
11.2.3.5.1.1. Market Estimation, 2015 - 2021
11.2.3.5.1.2. Market Forecast, 2022 – 2030
11.2.3.5.2.
Europe
11.2.3.5.2.1. Market Estimation, 2015 - 2021
11.2.3.5.2.2. Market Forecast, 2022 – 2030
11.2.3.5.3.
Asia
Pacific
11.2.3.5.3.1. Market Estimation, 2015 - 2021
11.2.3.5.3.2. Market Forecast, 2022 – 2030
11.2.3.5.4.
Middle
East and Africa
11.2.3.5.4.1. Market Estimation, 2015 - 2021
11.2.3.5.4.2. Market Forecast, 2022 – 2030
11.2.3.5.5.
Latin
America
11.2.3.5.5.1. Market Estimation, 2015 - 2021
11.2.3.5.5.2. Market Forecast, 2022 – 2030
11.2.4. Vitrectomy
11.2.4.1.
Definition
11.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.4.3.
Market
Forecast, 2022 – 2030
11.2.4.4.
Compound
Annual Growth Rate (CAGR)
11.2.4.5.
Regional
Bifurcation
11.2.4.5.1.
North
America
11.2.4.5.1.1. Market Estimation, 2015 - 2021
11.2.4.5.1.2. Market Forecast, 2022 – 2030
11.2.4.5.2.
Europe
11.2.4.5.2.1. Market Estimation, 2015 - 2021
11.2.4.5.2.2. Market Forecast, 2022 – 2030
11.2.4.5.3.
Asia
Pacific
11.2.4.5.3.1. Market Estimation, 2015 - 2021
11.2.4.5.3.2. Market Forecast, 2022 – 2030
11.2.4.5.4.
Middle
East and Africa
11.2.4.5.4.1. Market Estimation, 2015 - 2021
11.2.4.5.4.2. Market Forecast, 2022 – 2030
11.2.4.5.5.
Latin
America
11.2.4.5.5.1. Market Estimation, 2015 - 2021
11.2.4.5.5.2. Market Forecast, 2022 – 2030
11.2.5. Others
11.2.5.1.
Definition
11.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.5.3.
Market
Forecast, 2022 – 2030
11.2.5.4.
Compound
Annual Growth Rate (CAGR)
11.2.5.5.
Regional
Bifurcation
11.2.5.5.1.
North
America
11.2.5.5.1.1. Market Estimation, 2015 - 2021
11.2.5.5.1.2. Market Forecast, 2022 – 2030
11.2.5.5.2.
Europe
11.2.5.5.2.1. Market Estimation, 2015 - 2021
11.2.5.5.2.2. Market Forecast, 2022 – 2030
11.2.5.5.3.
Asia
Pacific
11.2.5.5.3.1. Market Estimation, 2015 - 2021
11.2.5.5.3.2. Market Forecast, 2022 – 2030
11.2.5.5.4.
Middle
East and Africa
11.2.5.5.4.1. Market Estimation, 2015 - 2021
11.2.5.5.4.2. Market Forecast, 2022 – 2030
11.2.5.5.5.
Latin
America
11.2.5.5.5.1. Market Estimation, 2015 - 2021
11.2.5.5.5.2. Market Forecast, 2022 – 2030
11.3. Key Segment for Channeling Investments
11.3.1. By Treatment
12. North America Diabetic Retinopathy Market
Analysis and Forecasts, 2022 – 2030
12.1. Overview
12.1.1. North America Diabetic Retinopathy Market
Revenue (US$ Mn)
12.2. North America Diabetic Retinopathy Market
Revenue (US$ Mn) and Forecasts, By Type
12.2.1. Nonproliferative Diabetic Retinopathy
12.2.2. Proliferative Diabetic Retinopathy
12.3. North America Diabetic Retinopathy Market
Revenue (US$ Mn) and Forecasts, By
Symptoms
12.3.1. Spots or dark strings floaters
12.3.2. Blurred vision
12.3.3. Fluctuating vision
12.3.4. Dark or empty areas in your vision
12.3.5. Vision loss
12.3.6. Others
12.4. North America Diabetic Retinopathy Market
Revenue (US$ Mn) and Forecasts, By Diagnosis
12.4.1. Fluorescein angiography
12.4.2. Optical coherence tomography (OCT)
12.5. North America Diabetic Retinopathy Market
Revenue (US$ Mn) and Forecasts, By Treatment
12.5.1. Anti VEGF Drug
12.5.2. Steroid Implants
12.5.3. Laser Surgeries
12.5.4. Vitrectomy
12.5.5. Others
12.6. North America Diabetic Retinopathy Market
Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1.
U.S Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
12.6.1.1.1.
Nonproliferative
Diabetic Retinopathy
12.6.1.1.2.
Proliferative
Diabetic Retinopathy
12.6.1.2.
U.S Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
12.6.1.2.1.
Spots or
dark strings floaters
12.6.1.2.2.
Blurred
vision
12.6.1.2.3.
Fluctuating
vision
12.6.1.2.4.
Dark or
empty areas in your vision
12.6.1.2.5.
Vision
loss
12.6.1.2.6.
Others
12.6.1.3.
U.S Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
12.6.1.3.1.
Fluorescein
angiography
12.6.1.3.2.
Optical
coherence tomography (OCT)
12.6.1.4.
U.S Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
12.6.1.4.1.
Anti
VEGF Drug
12.6.1.4.2.
Steroid Implants
12.6.1.4.3.
Laser
Surgeries
12.6.1.4.4.
Vitrectomy
12.6.1.4.5.
Others
12.6.2. Canada
12.6.2.1.
Canada Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
12.6.2.1.1.
Nonproliferative
Diabetic Retinopathy
12.6.2.1.2.
Proliferative
Diabetic Retinopathy
12.6.2.2.
Canada Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
12.6.2.2.1.
Spots or
dark strings floaters
12.6.2.2.2.
Blurred
vision
12.6.2.2.3.
Fluctuating
vision
12.6.2.2.4.
Dark or
empty areas in your vision
12.6.2.2.5.
Vision
loss
12.6.2.2.6.
Others
12.6.2.3.
Canada Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
12.6.2.3.1.
Fluorescein
angiography
12.6.2.3.2.
Optical
coherence tomography (OCT)
12.6.2.4.
Canada Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
12.6.2.4.1.
Anti
VEGF Drug
12.6.2.4.2.
Steroid
Implants
12.6.2.4.3.
Laser
Surgeries
12.6.2.4.4.
Vitrectomy
12.6.2.4.5.
Others
12.6.3. Mexico
12.6.3.1.
Mexico Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
12.6.3.1.1.
Nonproliferative
Diabetic Retinopathy
12.6.3.1.2.
Proliferative
Diabetic Retinopathy
12.6.3.2.
Mexico Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
12.6.3.2.1.
Spots or
dark strings floaters
12.6.3.2.2.
Blurred
vision
12.6.3.2.3.
Fluctuating
vision
12.6.3.2.4.
Dark or
empty areas in your vision
12.6.3.2.5.
Vision
loss
12.6.3.2.6.
Others
12.6.3.3.
Mexico Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
12.6.3.3.1.
Fluorescein
angiography
12.6.3.3.2.
Optical
coherence tomography (OCT)
12.6.3.4.
Mexico Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
12.6.3.4.1.
Anti
VEGF Drug
12.6.3.4.2.
Steroid
Implants
12.6.3.4.3.
Laser
Surgeries
12.6.3.4.4.
Vitrectomy
12.6.3.4.5.
Others
12.6.4. Rest of North America
12.6.4.1.
Rest of
North America Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts,
By Type
12.6.4.1.1.
Nonproliferative
Diabetic Retinopathy
12.6.4.1.2.
Proliferative
Diabetic Retinopathy
12.6.4.2.
Rest of
North America Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts,
By Symptoms
12.6.4.2.1.
Spots or
dark strings floaters
12.6.4.2.2.
Blurred
vision
12.6.4.2.3.
Fluctuating
vision
12.6.4.2.4.
Dark or
empty areas in your vision
12.6.4.2.5.
Vision
loss
12.6.4.2.6.
Others
12.6.4.3.
Rest of
North America Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
12.6.4.3.1.
Fluorescein
angiography
12.6.4.3.2.
Optical
coherence tomography (OCT)
12.6.4.4.
Rest of
North America Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By
Treatment
12.6.4.4.1.
Anti
VEGF Drug
12.6.4.4.2.
Steroid
Implants
12.6.4.4.3.
Laser
Surgeries
12.6.4.4.4.
Vitrectomy
12.6.4.4.5.
Others
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By
Type
12.7.3. By
Symptoms
12.7.4. By Diagnosis
12.7.5. By Treatment
13. Europe Diabetic Retinopathy Market Analysis
and Forecasts, 2022 – 2030
13.1. Overview
13.1.1. Europe Diabetic Retinopathy Market Revenue
(US$ Mn)
13.2. Europe Diabetic Retinopathy Market Revenue
(US$ Mn) and Forecasts, By Type
13.2.1. Nonproliferative Diabetic Retinopathy
13.2.2. Proliferative Diabetic Retinopathy
13.3. Europe Diabetic Retinopathy Market Revenue
(US$ Mn) and Forecasts, By Symptoms
13.3.1. Spots or dark strings floaters
13.3.2. Blurred vision
13.3.3. Fluctuating vision
13.3.4. Dark or empty areas in your vision
13.3.5. Vision loss
13.3.6. Others
13.4. Europe Diabetic Retinopathy Market Revenue
(US$ Mn) and Forecasts, By Diagnosis
13.4.1. Fluorescein angiography
13.4.2. Optical coherence tomography (OCT)
13.5. Europe Diabetic Retinopathy Market Revenue
(US$ Mn) and Forecasts, By Treatment
13.5.1. Anti VEGF Drug
13.5.2. Steroid Implants
13.5.3. Laser Surgeries
13.5.4. Vitrectomy
13.5.5. Others
13.6. Europe Diabetic Retinopathy Market Revenue
(US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1.
France Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
13.6.1.1.1.
Nonproliferative
Diabetic Retinopathy
13.6.1.1.2.
Proliferative
Diabetic Retinopathy
13.6.1.2.
France Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
13.6.1.2.1.
Spots or
dark strings floaters
13.6.1.2.2.
Blurred
vision
13.6.1.2.3.
Fluctuating
vision
13.6.1.2.4.
Dark or
empty areas in your vision
13.6.1.2.5.
Vision
loss
13.6.1.2.6.
Others
13.6.1.3.
France Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.6.1.3.1.
Fluorescein
angiography
13.6.1.3.2.
Optical
coherence tomography (OCT)
13.6.1.4.
France Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
13.6.1.4.1.
Anti
VEGF Drug
13.6.1.4.2.
Steroid
Implants
13.6.1.4.3.
Laser
Surgeries
13.6.1.4.4.
Vitrectomy
13.6.1.4.5.
Others
13.6.2. The UK
13.6.2.1.
The UK Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
13.6.2.1.1.
Nonproliferative
Diabetic Retinopathy
13.6.2.1.2.
Proliferative
Diabetic Retinopathy
13.6.2.2.
The UK Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
13.6.2.2.1.
Spots or
dark strings floaters
13.6.2.2.2.
Blurred
vision
13.6.2.2.3.
Fluctuating
vision
13.6.2.2.4.
Dark or
empty areas in your vision
13.6.2.2.5.
Vision
loss
13.6.2.2.6.
Others
13.6.2.3.
The UK Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.6.2.3.1.
Fluorescein
angiography
13.6.2.3.2.
Optical
coherence tomography (OCT)
13.6.2.4.
The UK Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
13.6.2.4.1.
Anti
VEGF Drug
13.6.2.4.2.
Steroid
Implants
13.6.2.4.3.
Laser
Surgeries
13.6.2.4.4.
Vitrectomy
13.6.2.4.5.
Others
13.6.3. Spain
13.6.3.1.
Spain Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
13.6.3.1.1.
Nonproliferative
Diabetic Retinopathy
13.6.3.1.2.
Proliferative
Diabetic Retinopathy
13.6.3.2.
Spain Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
13.6.3.2.1.
Spots or
dark strings floaters
13.6.3.2.2.
Blurred
vision
13.6.3.2.3.
Fluctuating
vision
13.6.3.2.4.
Dark or
empty areas in your vision
13.6.3.2.5.
Vision
loss
13.6.3.2.6.
Others
13.6.3.3.
Spain Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.6.3.3.1.
Fluorescein
angiography
13.6.3.3.2.
Optical
coherence tomography (OCT)
13.6.3.4.
Spain Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
13.6.3.4.1.
Anti
VEGF Drug
13.6.3.4.2.
Steroid
Implants
13.6.3.4.3.
Laser
Surgeries
13.6.3.4.4.
Vitrectomy
13.6.3.4.5.
Others
13.6.4. Germany
13.6.4.1.
Germany Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
13.6.4.1.1.
Nonproliferative
Diabetic Retinopathy
13.6.4.1.2.
Proliferative
Diabetic Retinopathy
13.6.4.2.
Germany Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
13.6.4.2.1.
Spots or
dark strings floaters
13.6.4.2.2.
Blurred
vision
13.6.4.2.3.
Fluctuating
vision
13.6.4.2.4.
Dark or
empty areas in your vision
13.6.4.2.5.
Vision
loss
13.6.4.2.6.
Others
13.6.4.3.
Germany Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.6.4.3.1.
Fluorescein
angiography
13.6.4.3.2.
Optical
coherence tomography (OCT)
13.6.4.4.
Germany Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
13.6.4.4.1.
Anti
VEGF Drug
13.6.4.4.2.
Steroid
Implants
13.6.4.4.3.
Laser
Surgeries
13.6.4.4.4.
Vitrectomy
13.6.4.4.5.
Others
13.6.5. Italy
13.6.5.1.
Italy Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
13.6.5.1.1.
Nonproliferative
Diabetic Retinopathy
13.6.5.1.2.
Proliferative
Diabetic Retinopathy
13.6.5.2.
Italy Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
13.6.5.2.1.
Spots or
dark strings floaters
13.6.5.2.2.
Blurred
vision
13.6.5.2.3.
Fluctuating
vision
13.6.5.2.4.
Dark or
empty areas in your vision
13.6.5.2.5.
Vision
loss
13.6.5.2.6.
Others
13.6.5.3.
Italy Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.6.5.3.1.
Fluorescein
angiography
13.6.5.3.2.
Optical
coherence tomography (OCT)
13.6.5.4.
Italy Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
13.6.5.4.1.
Anti
VEGF Drug
13.6.5.4.2.
Steroid
Implants
13.6.5.4.3.
Laser
Surgeries
13.6.5.4.4.
Vitrectomy
13.6.5.4.5.
Others
13.6.6. Nordic Countries
13.6.6.1.
Nordic
Countries Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
13.6.6.1.1.
Nonproliferative
Diabetic Retinopathy
13.6.6.1.2.
Proliferative
Diabetic Retinopathy
13.6.6.2.
Nordic
Countries Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
13.6.6.2.1.
Spots or
dark strings floaters
13.6.6.2.2.
Blurred
vision
13.6.6.2.3.
Fluctuating
vision
13.6.6.2.4.
Dark or
empty areas in your vision
13.6.6.2.5.
Vision
loss
13.6.6.2.6.
Others
13.6.6.3.
Nordic
Countries Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
13.6.6.3.1.
Fluorescein
angiography
13.6.6.3.2.
Optical
coherence tomography (OCT)
13.6.6.4.
Nordic
Countries Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
13.6.6.4.1.
Anti
VEGF Drug
13.6.6.4.2.
Steroid
Implants
13.6.6.4.3.
Laser
Surgeries
13.6.6.4.4.
Vitrectomy
13.6.6.4.5.
Others
13.6.6.5.
Nordic
Countries Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.6.5.1.
Denmark
13.6.6.5.2.
Finland
13.6.6.5.3.
Iceland
13.6.6.5.4.
Sweden
13.6.6.5.5.
Norway
13.6.7. Benelux Union
13.6.7.1.
Benelux
Union Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
13.6.7.1.1.
Nonproliferative
Diabetic Retinopathy
13.6.7.1.2.
Proliferative
Diabetic Retinopathy
13.6.7.2.
Benelux
Union Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
13.6.7.2.1.
Spots or
dark strings floaters
13.6.7.2.2.
Blurred
vision
13.6.7.2.3.
Fluctuating
vision
13.6.7.2.4.
Dark or
empty areas in your vision
13.6.7.2.5.
Vision
loss
13.6.7.2.6.
Others
13.6.7.3.
Benelux
Union Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.6.7.3.1.
Fluorescein
angiography
13.6.7.3.2.
Optical
coherence tomography (OCT)
13.6.7.4.
Benelux
Union Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
13.6.7.4.1.
Anti
VEGF Drug
13.6.7.4.2.
Steroid
Implants
13.6.7.4.3.
Laser
Surgeries
13.6.7.4.4.
Vitrectomy
13.6.7.4.5.
Others
13.6.7.5.
Benelux
Union Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1.
Belgium
13.6.7.5.2.
The
Netherlands
13.6.7.5.3.
Luxembourg
13.6.8. Rest of Europe
13.6.8.1.
Rest of
Europe Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
13.6.8.1.1.
Nonproliferative
Diabetic Retinopathy
13.6.8.1.2.
Proliferative
Diabetic Retinopathy
13.6.8.2.
Rest of
Europe Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
13.6.8.2.1.
Spots or
dark strings floaters
13.6.8.2.2.
Blurred
vision
13.6.8.2.3.
Fluctuating
vision
13.6.8.2.4.
Dark or
empty areas in your vision
13.6.8.2.5.
Vision
loss
13.6.8.2.6.
Others
13.6.8.3.
Rest of
Europe Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.6.8.3.1.
Fluorescein
angiography
13.6.8.3.2.
Optical
coherence tomography (OCT)
13.6.8.4.
Rest of
Europe Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
13.6.8.4.1.
Anti
VEGF Drug
13.6.8.4.2.
Steroid
Implants
13.6.8.4.3.
Laser
Surgeries
13.6.8.4.4.
Vitrectomy
13.6.8.4.5.
Others
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By
Type
13.7.3. By
Symptoms
13.7.4. By Diagnosis
13.7.5. By Treatment
14. Asia Pacific Diabetic Retinopathy Market
Analysis and Forecasts, 2022 – 2030
14.1. Overview
14.1.1. Asia Pacific Diabetic Retinopathy Market
Revenue (US$ Mn)
14.2. Asia Pacific Diabetic Retinopathy Market
Revenue (US$ Mn) and Forecasts, By Type
14.2.1. Nonproliferative Diabetic Retinopathy
14.2.2. Proliferative Diabetic Retinopathy
14.3. Asia Pacific Diabetic Retinopathy Market
Revenue (US$ Mn) and Forecasts, By
Symptoms
14.3.1. Spots or dark strings floaters
14.3.2. Blurred vision
14.3.3. Fluctuating vision
14.3.4. Dark or empty areas in your vision
14.3.5. Vision loss
14.3.6. Others
14.4. Asia Pacific Diabetic Retinopathy Market
Revenue (US$ Mn) and Forecasts, By Diagnosis
14.4.1. Fluorescein angiography
14.4.2. Optical coherence tomography (OCT)
14.5. Asia Pacific Diabetic Retinopathy Market
Revenue (US$ Mn) and Forecasts, By Treatment
14.5.1. Anti VEGF Drug
14.5.2. Steroid Implants
14.5.3. Laser Surgeries
14.5.4. Vitrectomy
14.5.5. Others
14.6. Asia Pacific Diabetic Retinopathy Market
Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1.
China Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
14.6.1.1.1.
Nonproliferative
Diabetic Retinopathy
14.6.1.1.2.
Proliferative
Diabetic Retinopathy
14.6.1.2.
China Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
14.6.1.2.1.
Spots or
dark strings floaters
14.6.1.2.2.
Blurred
vision
14.6.1.2.3.
Fluctuating
vision
14.6.1.2.4.
Dark or
empty areas in your vision
14.6.1.2.5.
Vision
loss
14.6.1.2.6.
Others
14.6.1.3.
China Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.6.1.3.1.
Fluorescein
angiography
14.6.1.3.2.
Optical
coherence tomography (OCT)
14.6.1.4.
China Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
14.6.1.4.1.
Anti
VEGF Drug
14.6.1.4.2.
Steroid
Implants
14.6.1.4.3.
Laser
Surgeries
14.6.1.4.4.
Vitrectomy
14.6.1.4.5.
Others
14.6.2. Japan
14.6.2.1.
Japan Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
14.6.2.1.1.
Nonproliferative
Diabetic Retinopathy
14.6.2.1.2.
Proliferative
Diabetic Retinopathy
14.6.2.2.
Japan Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
14.6.2.2.1.
Spots or
dark strings floaters
14.6.2.2.2.
Blurred
vision
14.6.2.2.3.
Fluctuating
vision
14.6.2.2.4.
Dark or
empty areas in your vision
14.6.2.2.5.
Vision
loss
14.6.2.2.6.
Others
14.6.2.3.
Japan Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.6.2.3.1.
Fluorescein
angiography
14.6.2.3.2.
Optical
coherence tomography (OCT)
14.6.2.4.
Japan Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
14.6.2.4.1.
Anti
VEGF Drug
14.6.2.4.2.
Steroid
Implants
14.6.2.4.3.
Laser
Surgeries
14.6.2.4.4.
Vitrectomy
14.6.2.4.5.
Others
14.6.3. India
14.6.3.1.
India Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
14.6.3.1.1.
Nonproliferative
Diabetic Retinopathy
14.6.3.1.2.
Proliferative
Diabetic Retinopathy
14.6.3.2.
India Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
14.6.3.2.1.
Spots or
dark strings floaters
14.6.3.2.2.
Blurred
vision
14.6.3.2.3.
Fluctuating
vision
14.6.3.2.4.
Dark or
empty areas in your vision
14.6.3.2.5.
Vision
loss
14.6.3.2.6.
Others
14.6.3.3.
India Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.6.3.3.1.
Fluorescein
angiography
14.6.3.3.2.
Optical
coherence tomography (OCT)
14.6.3.4.
India Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
14.6.3.4.1.
Anti
VEGF Drug
14.6.3.4.2.
Steroid
Implants
14.6.3.4.3.
Laser
Surgeries
14.6.3.4.4.
Vitrectomy
14.6.3.4.5.
Others
14.6.4. New Zealand
14.6.4.1.
New
Zealand Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
14.6.4.1.1.
Nonproliferative
Diabetic Retinopathy
14.6.4.1.2.
Proliferative
Diabetic Retinopathy
14.6.4.2.
New
Zealand Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
14.6.4.2.1.
Spots or
dark strings floaters
14.6.4.2.2.
Blurred
vision
14.6.4.2.3.
Fluctuating
vision
14.6.4.2.4.
Dark or
empty areas in your vision
14.6.4.2.5.
Vision
loss
14.6.4.2.6.
Others
14.6.4.3.
New
Zealand Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
14.6.4.3.1.
Fluorescein
angiography
14.6.4.3.2.
Optical
coherence tomography (OCT)
14.6.4.4.
New
Zealand Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By
Treatment
14.6.4.4.1.
Anti
VEGF Drug
14.6.4.4.2.
Steroid
Implants
14.6.4.4.3.
Laser
Surgeries
14.6.4.4.4.
Vitrectomy
14.6.4.4.5.
Others
14.6.5. Australia
14.6.5.1.
Australia
Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
14.6.5.1.1.
Nonproliferative
Diabetic Retinopathy
14.6.5.1.2.
Proliferative
Diabetic Retinopathy
14.6.5.2.
Australia
Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
14.6.5.2.1.
Spots or
dark strings floaters
14.6.5.2.2.
Blurred
vision
14.6.5.2.3.
Fluctuating
vision
14.6.5.2.4.
Dark or
empty areas in your vision
14.6.5.2.5.
Vision
loss
14.6.5.2.6.
Others
14.6.5.3.
Australia
Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.6.5.3.1.
Fluorescein
angiography
14.6.5.3.2.
Optical
coherence tomography (OCT)
14.6.5.4.
Australia
Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
14.6.5.4.1.
Anti
VEGF Drug
14.6.5.4.2.
Steroid Implants
14.6.5.4.3.
Laser
Surgeries
14.6.5.4.4.
Vitrectomy
14.6.5.4.5.
Others
14.6.6. South Korea
14.6.6.1.
South
Korea Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
14.6.6.1.1.
Nonproliferative
Diabetic Retinopathy
14.6.6.1.2.
Proliferative
Diabetic Retinopathy
14.6.6.2.
South
Korea Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
14.6.6.2.1.
Spots or
dark strings floaters
14.6.6.2.2.
Blurred
vision
14.6.6.2.3.
Fluctuating
vision
14.6.6.2.4.
Dark or
empty areas in your vision
14.6.6.2.5.
Vision
loss
14.6.6.2.6.
Others
14.6.6.3.
South
Korea Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.6.6.3.1.
Fluorescein
angiography
14.6.6.3.2.
Optical
coherence tomography (OCT)
14.6.6.4.
South
Korea Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
14.6.6.4.1.
Anti
VEGF Drug
14.6.6.4.2.
Steroid
Implants
14.6.6.4.3.
Laser
Surgeries
14.6.6.4.4.
Vitrectomy
14.6.6.4.5.
Others
14.6.7. Southeast Asia
14.6.7.1.
Southeast
Asia Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
14.6.7.1.1.
Nonproliferative
Diabetic Retinopathy
14.6.7.1.2.
Proliferative
Diabetic Retinopathy
14.6.7.2.
Southeast
Asia Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
14.6.7.2.1.
Spots or
dark strings floaters
14.6.7.2.2.
Blurred
vision
14.6.7.2.3.
Fluctuating
vision
14.6.7.2.4.
Dark or
empty areas in your vision
14.6.7.2.5.
Vision
loss
14.6.7.2.6.
Others
14.6.7.3.
Southeast
Asia Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.6.7.3.1.
Fluorescein
angiography
14.6.7.3.2.
Optical
coherence tomography (OCT)
14.6.7.4.
Southeast
Asia Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
14.6.7.4.1.
Anti
VEGF Drug
14.6.7.4.2.
Steroid
Implants
14.6.7.4.3.
Laser
Surgeries
14.6.7.4.4.
Vitrectomy
14.6.7.4.5.
Others
14.6.7.5.
Southeast
Asia Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1.
Indonesia
14.6.7.5.2.
Thailand
14.6.7.5.3.
Malaysia
14.6.7.5.4.
Singapore
14.6.7.5.5.
Rest of
Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1.
Rest of
Asia Pacific Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts,
By Type
14.6.8.1.1.
Nonproliferative
Diabetic Retinopathy
14.6.8.1.2.
Proliferative
Diabetic Retinopathy
14.6.8.2.
Rest of
Asia Pacific Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts,
By Symptoms
14.6.8.2.1.
Spots or
dark strings floaters
14.6.8.2.2.
Blurred
vision
14.6.8.2.3.
Fluctuating
vision
14.6.8.2.4.
Dark or
empty areas in your vision
14.6.8.2.5.
Vision
loss
14.6.8.2.6.
Others
14.6.8.3.
Rest of
Asia Pacific Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
14.6.8.3.1.
Fluorescein
angiography
14.6.8.3.2.
Optical
coherence tomography (OCT)
14.6.8.4.
Rest of
Asia Pacific Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By
Treatment
14.6.8.4.1.
Anti
VEGF Drug
14.6.8.4.2.
Steroid
Implants
14.6.8.4.3.
Laser
Surgeries
14.6.8.4.4.
Vitrectomy
14.6.8.4.5.
Others
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2. By
Type
14.7.3. By
Symptoms
14.7.4. By Diagnosis
14.7.5. By Treatment
15. Middle East and Africa Diabetic Retinopathy
Market Analysis and Forecasts, 2022 – 2030
15.1. Overview
15.1.1. Middle East and Africa Diabetic Retinopathy
Market Revenue (US$ Mn)
15.2. Middle East and Africa Diabetic Retinopathy
Market Revenue (US$ Mn) and Forecasts, By
Type
15.2.1. Nonproliferative Diabetic Retinopathy
15.2.2. Proliferative Diabetic Retinopathy
15.3. Middle East and Africa Diabetic Retinopathy
Market Revenue (US$ Mn) and Forecasts, By
Symptoms
15.3.1. Spots or dark strings floaters
15.3.2. Blurred vision
15.3.3. Fluctuating vision
15.3.4. Dark or empty areas in your vision
15.3.5. Vision loss
15.3.6. Others
15.4. Middle East and Africa Diabetic Retinopathy
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.4.1. Fluorescein angiography
15.4.2. Optical coherence tomography (OCT)
15.5. Middle East and Africa Diabetic Retinopathy
Market Revenue (US$ Mn) and Forecasts, By Treatment
15.5.1. Anti VEGF Drug
15.5.2. Steroid Implants
15.5.3. Laser Surgeries
15.5.4. Vitrectomy
15.5.5. Others
15.6. Middle East and Africa Diabetic Retinopathy
Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1.
Saudi
Arabia Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
15.6.1.1.1.
Nonproliferative
Diabetic Retinopathy
15.6.1.1.2.
Proliferative
Diabetic Retinopathy
15.6.1.2.
Saudi
Arabia Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
15.6.1.2.1.
Spots or
dark strings floaters
15.6.1.2.2.
Blurred
vision
15.6.1.2.3.
Fluctuating
vision
15.6.1.2.4.
Dark or
empty areas in your vision
15.6.1.2.5.
Vision
loss
15.6.1.2.6.
Others
15.6.1.3.
Saudi
Arabia Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.6.1.3.1.
Fluorescein
angiography
15.6.1.3.2.
Optical
coherence tomography (OCT)
15.6.1.4.
Saudi
Arabia Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
15.6.1.4.1.
Anti
VEGF Drug
15.6.1.4.2.
Steroid
Implants
15.6.1.4.3.
Laser
Surgeries
15.6.1.4.4.
Vitrectomy
15.6.1.4.5.
Others
15.6.2. UAE
15.6.2.1.
UAE Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
15.6.2.1.1.
Nonproliferative
Diabetic Retinopathy
15.6.2.1.2.
Proliferative
Diabetic Retinopathy
15.6.2.2.
UAE Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
15.6.2.2.1.
Spots or
dark strings floaters
15.6.2.2.2.
Blurred
vision
15.6.2.2.3.
Fluctuating
vision
15.6.2.2.4.
Dark or
empty areas in your vision
15.6.2.2.5.
Vision
loss
15.6.2.2.6.
Others
15.6.2.3.
UAE Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.6.2.3.1.
Fluorescein
angiography
15.6.2.3.2.
Optical
coherence tomography (OCT)
15.6.2.4.
UAE Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
15.6.2.4.1.
Anti
VEGF Drug
15.6.2.4.2.
Steroid
Implants
15.6.2.4.3.
Laser
Surgeries
15.6.2.4.4.
Vitrectomy
15.6.2.4.5.
Others
15.6.3. Egypt
15.6.3.1.
Egypt Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
15.6.3.1.1.
Nonproliferative
Diabetic Retinopathy
15.6.3.1.2.
Proliferative
Diabetic Retinopathy
15.6.3.2.
Egypt Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
15.6.3.2.1.
Spots or
dark strings floaters
15.6.3.2.2.
Blurred
vision
15.6.3.2.3.
Fluctuating
vision
15.6.3.2.4.
Dark or
empty areas in your vision
15.6.3.2.5.
Vision
loss
15.6.3.2.6.
Others
15.6.3.3.
Egypt Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.6.3.3.1.
Fluorescein
angiography
15.6.3.3.2.
Optical
coherence tomography (OCT)
15.6.3.4.
Egypt Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
15.6.3.4.1.
Anti
VEGF Drug
15.6.3.4.2.
Steroid
Implants
15.6.3.4.3.
Laser
Surgeries
15.6.3.4.4.
Vitrectomy
15.6.3.4.5.
Others
15.6.4. Kuwait
15.6.4.1.
Kuwait Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
15.6.4.1.1.
Nonproliferative
Diabetic Retinopathy
15.6.4.1.2.
Proliferative
Diabetic Retinopathy
15.6.4.2.
Kuwait Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
15.6.4.2.1.
Spots or
dark strings floaters
15.6.4.2.2.
Blurred
vision
15.6.4.2.3.
Fluctuating
vision
15.6.4.2.4.
Dark or
empty areas in your vision
15.6.4.2.5.
Vision
loss
15.6.4.2.6.
Others
15.6.4.3.
Kuwait Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.6.4.3.1.
Fluorescein
angiography
15.6.4.3.2.
Optical
coherence tomography (OCT)
15.6.4.4.
Kuwait Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
15.6.4.4.1.
Anti
VEGF Drug
15.6.4.4.2.
Steroid
Implants
15.6.4.4.3.
Laser
Surgeries
15.6.4.4.4.
Vitrectomy
15.6.4.4.5.
Others
15.6.5. South Africa
15.6.5.1.
South
Africa Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
15.6.5.1.1.
Nonproliferative
Diabetic Retinopathy
15.6.5.1.2.
Proliferative
Diabetic Retinopathy
15.6.5.2.
South
Africa Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
15.6.5.2.1.
Spots or
dark strings floaters
15.6.5.2.2.
Blurred
vision
15.6.5.2.3.
Fluctuating
vision
15.6.5.2.4.
Dark or
empty areas in your vision
15.6.5.2.5.
Vision
loss
15.6.5.2.6.
Others
15.6.5.3.
South
Africa Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.6.5.3.1.
Fluorescein
angiography
15.6.5.3.2.
Optical
coherence tomography (OCT)
15.6.5.4.
South
Africa Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
15.6.5.4.1.
Anti
VEGF Drug
15.6.5.4.2.
Steroid
Implants
15.6.5.4.3.
Laser
Surgeries
15.6.5.4.4.
Vitrectomy
15.6.5.4.5.
Others
15.6.6. Rest of Middle East & Africa
15.6.6.1.
Rest of
Middle East & Africa Diabetic Retinopathy Market Revenue (US$ Mn) and
Forecasts, By Type
15.6.6.1.1.
Nonproliferative
Diabetic Retinopathy
15.6.6.1.2.
Proliferative
Diabetic Retinopathy
15.6.6.2.
Rest of
Middle East & Africa Diabetic Retinopathy Market Revenue (US$ Mn) and
Forecasts, By Symptoms
15.6.6.2.1.
Spots or
dark strings floaters
15.6.6.2.2.
Blurred
vision
15.6.6.2.3.
Fluctuating
vision
15.6.6.2.4.
Dark or
empty areas in your vision
15.6.6.2.5.
Vision
loss
15.6.6.2.6.
Others
15.6.6.3.
Rest of
Middle East & Africa Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
15.6.6.3.1.
Fluorescein
angiography
15.6.6.3.2.
Optical
coherence tomography (OCT)
15.6.6.4.
Rest of
Middle East & Africa Diabetic Retinopathy Market Revenue (US$ Mn) and
Forecasts, By Treatment
15.6.6.4.1.
Anti
VEGF Drug
15.6.6.4.2.
Steroid
Implants
15.6.6.4.3.
Laser
Surgeries
15.6.6.4.4.
Vitrectomy
15.6.6.4.5.
Others
15.7. Key Segment for Channeling Investments
15.7.1. By Country
15.7.2. By
Type
15.7.3. By
Symptoms
15.7.4. By Diagnosis
15.7.5. By Treatment
16. Latin America Diabetic Retinopathy Market
Analysis and Forecasts, 2022 – 2030
16.1. Overview
16.1.1. Latin America Diabetic Retinopathy Market
Revenue (US$ Mn)
16.2. Latin America Diabetic Retinopathy Market
Revenue (US$ Mn) and Forecasts, By Type
16.2.1. Nonproliferative Diabetic Retinopathy
16.2.2. Proliferative Diabetic Retinopathy
16.3. Latin America Diabetic Retinopathy Market
Revenue (US$ Mn) and Forecasts, By
Symptoms
16.3.1. Spots or dark strings floaters
16.3.2. Blurred vision
16.3.3. Fluctuating vision
16.3.4. Dark or empty areas in your vision
16.3.5. Vision loss
16.3.6. Others
16.4. Latin America Diabetic Retinopathy Market
Revenue (US$ Mn) and Forecasts, By Diagnosis
16.4.1. Fluorescein angiography
16.4.2. Optical coherence tomography (OCT)
16.5. Latin America Diabetic Retinopathy Market
Revenue (US$ Mn) and Forecasts, By Treatment
16.5.1. Anti VEGF Drug
16.5.2. Steroid Implants
16.5.3. Laser Surgeries
16.5.4. Vitrectomy
16.5.5. Others
16.6. Latin America Diabetic Retinopathy Market
Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1.
Brazil Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
16.6.1.1.1.
Nonproliferative
Diabetic Retinopathy
16.6.1.1.2.
Proliferative
Diabetic Retinopathy
16.6.1.2.
Brazil Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
16.6.1.2.1.
Spots or
dark strings floaters
16.6.1.2.2.
Blurred
vision
16.6.1.2.3.
Fluctuating
vision
16.6.1.2.4.
Dark or
empty areas in your vision
16.6.1.2.5.
Vision
loss
16.6.1.2.6.
Others
16.6.1.3.
Brazil Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
16.6.1.3.1.
Fluorescein
angiography
16.6.1.3.2.
Optical
coherence tomography (OCT)
16.6.1.4.
Brazil Diabetic
Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
16.6.1.4.1.
Anti
VEGF Drug
16.6.1.4.2.
Steroid
Implants
16.6.1.4.3.
Laser
Surgeries
16.6.1.4.4.
Vitrectomy
16.6.1.4.5.
Others
16.6.2. Argentina
16.6.2.1.
Argentina
Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Type
16.6.2.1.1.
Nonproliferative
Diabetic Retinopathy
16.6.2.1.2.
Proliferative
Diabetic Retinopathy
16.6.2.2.
Argentina
Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Symptoms
16.6.2.2.1.
Spots or
dark strings floaters
16.6.2.2.2.
Blurred
vision
16.6.2.2.3.
Fluctuating
vision
16.6.2.2.4.
Dark or
empty areas in your vision
16.6.2.2.5.
Vision
loss
16.6.2.2.6.
Others
16.6.2.3.
Argentina
Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Diagnosis
16.6.2.3.1.
Fluorescein
angiography
16.6.2.3.2.
Optical
coherence tomography (OCT)
16.6.2.4.
Argentina
Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By Treatment
16.6.2.4.1.
Anti
VEGF Drug
16.6.2.4.2.
Steroid
Implants
16.6.2.4.3.
Laser
Surgeries
16.6.2.4.4.
Vitrectomy
16.6.2.4.5.
Others
16.6.3. Rest of Latin America
16.6.3.1.
Rest of
Latin America Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts,
By Type
16.6.3.1.1.
Nonproliferative
Diabetic Retinopathy
16.6.3.1.2.
Proliferative
Diabetic Retinopathy
16.6.3.2.
Rest of
Latin America Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts,
By Symptoms
16.6.3.2.1.
Spots or
dark strings floaters
16.6.3.2.2.
Blurred
vision
16.6.3.2.3.
Fluctuating
vision
16.6.3.2.4.
Dark or
empty areas in your vision
16.6.3.2.5.
Vision
loss
16.6.3.2.6.
Others
16.6.3.3.
Rest of
Latin America Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
16.6.3.3.1.
Fluorescein
angiography
16.6.3.3.2.
Optical
coherence tomography (OCT)
16.6.3.4.
Rest of
Latin America Diabetic Retinopathy Market Revenue (US$ Mn) and Forecasts, By
Treatment
16.6.3.4.1.
Anti
VEGF Drug
16.6.3.4.2.
Steroid
Implants
16.6.3.4.3.
Laser
Surgeries
16.6.3.4.4.
Vitrectomy
16.6.3.4.5.
Others
16.7. Key Segment for Channeling Investments
16.7.1. By Country
16.7.2. By
Type
16.7.3. By
Symptoms
16.7.4. By Diagnosis
16.7.5. By Treatment
17. Competitive Benchmarking
17.1. Brand Benchmarking
17.2. Market Share Analysis, 2021
17.3. Global Presence and Growth Strategies
17.3.1. Mergers and Acquisitions
17.3.2. Product Launches
17.3.3. Investments Trends
17.3.4. R&D Initiatives
18. Player Profiles
18.1. Abbott
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. AbbVie Inc.
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. ALLERGAN
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. Ampio Pharmaceuticals, Inc.
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. Bayer AG
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. BCN Peptides S.A.
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. Genentech, Inc
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. Novartis AG
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. Pfizer Inc
18.9.1. Company Details
18.9.2. Company Overview
18.9.3. Product Offerings
18.9.4. Key Developments
18.9.5. Financial Analysis
18.9.6. SWOT Analysis
18.9.7. Business Strategies
18.10. Regeneron Pharmaceuticals Inc.
18.10.1. Company Details
18.10.2. Company Overview
18.10.3. Product Offerings
18.10.4. Key Developments
18.10.5. Financial Analysis
18.10.6. SWOT Analysis
18.10.7. Business Strategies
18.11. Sirnaomics Ltd.
18.11.1. Company Details
18.11.2. Company Overview
18.11.3. Product Offerings
18.11.4. Key Developments
18.11.5. Financial Analysis
18.11.6. SWOT Analysis
18.11.7. Business Strategies
18.12. Other Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
